Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm to identify and triage patients suspected of suffering from HCM.
Newly-appointed leader has served as the national or international principal investigator for more than 100 national and international randomized trials.
Expanded indication allows opportunity to provide longer duration of support for critically ill patients and a longer period of assessment of heart recovery.